 Pharmaceutical Research and Manufacturers of America (PhRMA, pronounced ), founded in 1958, is a trade group representing the pharmaceutical research and biopharmaceutical companies in the United States. PhRMA's stated mission is advocacy for public policies that encourage the discovery of new medicines for patients by pharmaceutical and biopharmaceutical research companies. PhRMA's current CEO is John J. Castellani. On its website, PhRMA states its "mission is winning advocacy for public policies that encourage the discovery of life-saving and life-enhancing new medicines for patients by pharmaceutical / biotechnology research companies. To accomplish this mission, PhRMA is dedicated to achieving in Washington, D.C., the states and the world: Tauzin started as CEO in 2005 and continued until he stepped down in 2010. Chris Viehbacher is the Chairman of PhRMA's board of directors. Since 2008 Viehbacher has also served as CEO of Sanofi-Aventis. He was born on 26 March 1960. He holds both German and Canadian nationalities. Viebacher is a certified public accountant. He graduated from Queens University in Canada. John J. Castellani is President and CEO of PhRMA. Castellani has promised that PhRMA will continue to support healthcare reform efforts in the United States and abroad. Specifically, PhRMA will focus on helping to successfully implement and improve the health reform legislation passed in 2010 under President Obama with a particular emphasis on rewarding innovation.Jeffrey Kindler, the chairman of Pfizer and former chairman of PhRMA, when commenting on Castellani's move from the Business Roundtable to PhRMA, said, “John is the gold standard, and I’m extremely pleased that he will lead our team." Mr. Castellani succeeds Billy Tauzin, a former Republican congressman from Louisiana. Jeffery Bond, representing PhRMA, sits on the Private Enterprise Board of the American Legislative Exchange Council (ALEC). Every year, PhRMA makes substantial efforts with regard to Special 301 Report issued by the Office of the United States Trade Representative on the enforcement of intellectual property laws abroad. PhRMA's recommendations for the Special 301 Report in 2009 were especially critical of the Philippines for "breaking patents" and failing to abide by the Agreement on Trade-Related Aspects of Intellectual Property Rights, commonly known as TRIPS. SMARxT Disposal is a joint program run by the U.S. Fish and Wildlife Service, the American Pharmacists Association, and PhRMA to encourage consumers to properly dispose of unused medicines in order to avoid harm to the environment. The Partnership for Prescription Assistance is a program by PhRMA and its member companies that connects patients in-need with information on low-cost and free prescription medication. Some prominent members of PhRMA include the following. A full list of members is available at the PhRMA website. 
